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Collaborative One Health approaches can mitigate increasing 
azole-resistant Aspergillus fumigatus in Africa
Aspergillus fumigatus is a species of fungus that is 
commonly found in the environment, household dust, 
soil, and decaying plant matter. The fungus produces 
spores which are inhaled by humans daily, although 
the host defence mechanisms of most people limit 
inflammatory responses and promote fungal clearance. 
Inhalation of the spores of A fumigatus triggers 
a wide spectrum of diseases in immunocompromised 
individuals, depending on the patient group 
affected and the pathways of pathogenesis. Forms 
of aspergillosis that are becoming a major public 
health issue include invasive aspergillosis, allergic 
bronchopulmonary aspergillosis, and chronic pulmonary 
aspergillosis.
Estimates suggest that approximately 2·2 million people 
suffer from invasive aspergillosis annually worldwide,1 
and it mostly occurs in immunocompromised individuals 
with chronic obstructive pulmonary disease, tuberculosis, 
or leukaemia, and more recently, as a complication of 
COVID-19. Left untreated, invasive aspergillosis is fatal.
Triazole antifungals are used for the prophylaxis 
and treatment of invasive fungal infections, acting 
by inhibiting the ergosterol biosynthesis pathway 
and disrupting the fungal cell membrane. Surveillance 
studies from various geographical locations have 
reported an increase in triazole-resistant A fumigatus 
(TRAF), raising concerns about the management of 
diseases caused by the fungus.2
The underlying resistance mechanism commonly 
involves point mutations in the cyp51A gene, with 
occasional non-cyp51 mutations. TRAF precludes the 
use of oral antifungals for treating aspergillosis, leaving 
only intravenous options, such as amphotericin B and 
echinocandins, which are not available in many African 
countries. The growing reports of TRAF have been 
linked to the use of fungicides in agriculture, with the 
development of cross-resistance to medical triazoles.
There have been several reports of TRAF from the 
eastern and western African subregions following 
the first report from Tanzania in 2014 (appendix).3–10 
In Tanzania and Kenya, TRAF was identified in both 
environmental and clinical samples, with isolation rates 
ranging from 14% to 27%.3–7 In one study, all five clinical 
isolates of A fumigatus were triazole resistant, giving 
a prevalence of 100%,4 with the TR34/L98H mutation 
being the predominant resistance phenotype in soils in 
Tanzania and Kenya. The TR46/Y121F/T289A mutation 
has also been detected in Tanzania, with all six clinical 
isolates seen so far—predominantly in cases of otitis 
media—bearing the TR34/L98H mutation (appendix).
Chowdhary and colleagues3 found a genetic 
relatedness of Tanzanian TR46/Y121F/T289A strains 
to Dutch isolates, and the TR34/L98H isolates were 
identical to the Indian TR34/L98H genotype.3,7 These 
similarities in molecular epidemiology suggest possible 
migration of isolates harbouring resistance traits from 
distant locales. In Kenya, although the prevalence of 
TRAF was higher in fungicide-experienced soil, TRAF 
was also present in fungicide-naive soil samples.5 This 
finding implies that TRAF might spread locally from 
areas of fungicide use to places where fungicides have 
not been used.
More recently, TRAF has been isolated from 
environmental samples in Burkina Faso and Nigeria.9,10 
Unlike in east Africa, TRAF isolation rates have been 
low, ranging from 2·0% to 2·2%, and tandem repeat 
mutations have not been identified. The cyp51A 
gene mutations detected in TRAF from Burkina Faso 
and Nigeria were F46Y/M172V/E427K and M172V 
respectively (appendix).9,10
Despite the absence of surveillance data on TRAF from 
other African countries, there is a possibility that TRAF 
is more widespread, given the extensive use of azole 
fungicides for agricultural purposes in the continent.9 
The inherent ability of A fumigatus to sporulate and 
survive in almost any environment facilitates its 
dispersal across long distances, with potential for 
transmission across national boundaries.
Given the interconnectedness of humans, plants, 
and animals in shared environments, tackling the 
problem of TRAF in Africa will require innovative, 
collaborative, multisectoral, and transdisciplinary One 
Health approaches. Greater collaboration between 
the agricultural and health sectors within Africa is 
urgently required. One Health policy adoptions and 
greater funding by African governments will catalyse 
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coordinated data sharing, interdisciplinary surveillance, 
and laboratory collaboration on TRAF. Existing public–
private partnerships such as the Africa One Health 
University Network could be leveraged to promote 
resource sharing and economies of scale.
Community engagement and advocacy are crucial 
to promote the adoption of safer and sustainable 
agricultural practices. Alternative strategies to 
community practices such as the use of azole 
fungicides should be promoted, along with a 
more judicious use of triazoles in clinical settings. 
Chemosensitisation, which involves the use of natural 
compounds that interact synergistically with antifungals 
thereby lowering effective dosages and negative 
effects, holds great promise in this regard. Coordinated 
capacity-building and research are crucial for identifying 
and responding to clinical and environmental TRAF in 
Africa. Urgent action is required to address TRAF and its 
attendant challenges in Africa, and adopting One Health 
approaches might be the turning point.
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